News in other languages : HANDOK Inc.

27/07/23

Hogere omzet en kleiner verlies voor Argenx

Managers and Directors : HANDOK Inc.

Manager	Title	Age	Since
Jin-Ki Baik CEO	Chief Executive Officer	69	-
Young-Jin Kim CEO	Chief Executive Officer	68	01/01/1996
Hyeon-Cheol Lee DFI	Director of Finance/CFO	58	-

Director	Title	Age	Since
Young-Jin Kim CHM	Chairman	68	01/01/1996
Jin-Ki Baik BRD	Director/Board Member	69	-
Young Kim BRD	Director/Board Member	58	-

More insiders

Handok Inc is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment mainly manufactures and sells prescription and over-the-counter drugs, including treatments for diabetes, hypertension, kidney diseases, respiratory diseases, central nervous system disorders, rare diseases, as well as anticancer drugs. The Medical Device segment mainly sells medical devices and diagnostic reagents. The Contract Manufacturing segment mainly provides contract manufacturing and quality control services for pharmaceuticals. The Real Estate Leasing segment mainly engages in the real estate leasing business.

Employees

910

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	₩9,460.00	0.00%	6,660
10/09/26	₩9,460.00	+0.11%	6,122
09/09/26	₩9,450.00	+0.32%	2,143
08/09/26	₩9,420.00	-1.15%	17,722
07/09/26	₩9,530.00	0.00%	7,174

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 11/09/2026			5-day change	1st Jan Change
9,460.00 ^KRW	0.00%		-0.73%	-15.54%

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-11	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI

Market Cap	123B 91.68M 78.99M 74.8M 67.79M 127M 8.76B 128M 888M 342M 4.46B 344M 337M 14.08B	P/E 2024	-3.16x	P/E 2025	-69x
Enterprise Value	473B 353M 304M 288M 261M 490M 33.74B 492M 3.42B 1.32B 17.17B 1.33B 1.3B 54.24B	EV / Sales 2024	0.95x	EV / Sales 2025	0.93x
Free-Float	52.22%	Yield 2024	1.66%	Yield 2025	-

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-11	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI
02-10	Handok Q4 operating profit 4.2 billion won, swings to profit from year earlier	RE
30/10/25	Handok Q3 operating profit 287 million won, swings to profit from year earlier	RE
10/09/25	Teva Handok Announces UZEDY Receives Regulatory Approval from the South Korean Ministry of Food and Drug Safety	CI
12/05/25	Handok To Divest 9 Billion Won Worth Of Own Shares	RE
30/04/25	Handok Q1 Operating Loss 1.6 Billion Won	RE
05/02/25	Handok Q4 Operating Loss 2.7 Billion Won	RE
09/12/24	HANDOK Inc. announced that it expects to receive KRW 30 billion in funding	CI
26/06/24	WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	CI
24/05/24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT
24/05/24	Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	CI
16/04/24	Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	MT

14/02/24	Sobi and Handok establish joint venture for rare disease business in South Korea	AQ
03/04/17	Handok : Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017	BU

HANDOK Inc. Stock

Stocks

A002390

KR7002390003

Pharmaceuticals

Valuation : HANDOK Inc.

Chart: HANDOK Inc.

Latest news : HANDOK Inc.

Press Releases : HANDOK Inc.

News in other languages : HANDOK Inc.

Quotes and Performance

Price Extremes

Managers and Directors : HANDOK Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	-0.73%
Current month	-0.53%
1 month	-1.25%
3 months	+20.05%
6 months	-11.09%
Current year	-15.54%

1 week	9,270	9,610
1 month	9,000	9,900
Current year	6,460	11,820
1 year	6,460	12,150
3 years	6,460	20,300
5 years	6,460	26,500
10 years	6,460	44,750

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HANDOK INC.	0.00%	-0.73%	-19.63%	-29.93%	91.68M
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.70%	+86.30%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+49.15%	+61.95%	640B
ABBVIE INC.	+0.83%	+0.26%	+17.76%	+70.10%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+30.13%	+34.14%	337B
NOVARTIS AG	-0.09%	-13.54%	+13.34%	+24.74%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-0.73%	+10.64%	246B
AMGEN INC.	-1.34%	-13.70%	+36.53%	+46.70%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.63%	-58.97%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+25.46%	+85.90%	178B
Average	-0.65%	-5.26%	+17.91%	+33.16%	350.49B
Weighted average by Cap.	-0.51%	-4.42%	+30.96%	+54.65%

	2024	2025
Net sales	507B 378M 326M 309M 280M 525M 36.16B 528M 3.67B 1.41B 18.4B 1.42B 1.39B 58.13B	535B 399M 344M 326M 295M 554M 38.14B 557M 3.87B 1.49B 19.4B 1.5B 1.47B 61.31B
Net income	-52.56B -39.21M -33.79M -31.99M -29M -54.4M -3.75B -54.67M -380M -146M -1.91B -147M -144M -6.02B	-2.15B -1.61M -1.38M -1.31M -1.19M -2.23M -153M -2.24M -15.56M -5.98M -78.07M -6.03M -5.9M -247M
Net Debt	317B 237M 204M 193M 175M 328M 22.62B 330M 2.29B 882M 11.51B 889M 870M 36.36B	351B 261M 225M 213M 193M 363M 24.98B 365M 2.53B 974M 12.71B 982M 960M 40.16B